FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma

Case Medical Research ◽

10.31525/cmr-21d601b ◽

2019 ◽

Author(s):

Keyword(s):

Mantle Cell Lymphoma ◽

Cell Lymphoma ◽

Mantle Cell ◽

Accelerated Approval

Download Full-text

FDA grants accelerated approval to acalabrutinib for mantle cell lymphoma

Case Medical Research ◽

10.31525/fda1-ucm583106.htm ◽

2017 ◽

Author(s):

Keyword(s):

Mantle Cell Lymphoma ◽

Cell Lymphoma ◽

Mantle Cell ◽

Accelerated Approval

Download Full-text

Decision letter for "Radiotherapy in mantle cell lymphoma: a literature review"

10.1002/hon.2708/v2/decision1 ◽

2019 ◽

Keyword(s):

Literature Review ◽

Mantle Cell Lymphoma ◽

Cell Lymphoma ◽

Mantle Cell

Download Full-text

Mantle Cell Lymphoma Rising in Association with Inverted Papilloma

10.1055/s-0039-1679844 ◽

2019 ◽

Author(s):

Charles Tong ◽

Peter Papagiannopoulos ◽

Michael Feldman ◽

Nithin Adappa ◽

James Palmer

Keyword(s):

Mantle Cell Lymphoma ◽

Cell Lymphoma ◽

Inverted Papilloma ◽

Mantle Cell

Download Full-text

Mantle Cell Lymphoma Presenting with Unusual Morphology in an Adolescent Female: A Case Report and Review of the Literature

Pediatric and Developmental Pathology ◽

10.2350/06-08-0142 ◽

2006 ◽

Vol preprint (2007) ◽

pp. 1

Author(s):

Kristi Smock ◽

Hassan Yaish ◽

Mitchell Cairo ◽

Mark Lones ◽

Carlynn Willmore-Payne ◽

...

Keyword(s):

Case Report ◽

Mantle Cell Lymphoma ◽

Cell Lymphoma ◽

Adolescent Female ◽

Review Of The Literature ◽

Mantle Cell

Download Full-text

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Case Medical Research ◽

10.31525/ct1-nct03877055 ◽

2019 ◽

Author(s):

Keyword(s):

Mantle Cell Lymphoma ◽

Cell Lymphoma ◽

Mantle Cell

Download Full-text

Faculty Opinions recommendation of Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1248959.717057 ◽

2009 ◽

Author(s):

Michael Williams

Keyword(s):

Mantle Cell Lymphoma ◽

Phase Ii ◽

Phase Ii Study ◽

Cell Lymphoma ◽

Ibritumomab Tiuxetan ◽

Mantle Cell ◽

Yttrium 90

Download Full-text

Faculty Opinions recommendation of Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297959.792752812 ◽

2012 ◽

Author(s):

Nicolas Mounier

Keyword(s):

Mantle Cell Lymphoma ◽

Minimal Residual Disease ◽

Feasibility Study ◽

Residual Disease ◽

Cell Lymphoma ◽

Disease Monitoring ◽

Lymphoid Malignancies ◽

Minimal Residual Disease Monitoring ◽

Mantle Cell ◽

Minimal Residual

Download Full-text

Faculty Opinions recommendation of Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954686.793461217 ◽

2012 ◽

Author(s):

Nicolas Mounier

Keyword(s):

Mantle Cell Lymphoma ◽

Phase Ii ◽

Phase Ii Study ◽

Cell Lymphoma ◽

Eastern Cooperative Oncology Group ◽

Oncology Group ◽

Ibritumomab Tiuxetan ◽

Oncology Group Study ◽

Mantle Cell ◽

Yttrium 90

Download Full-text

Faculty Opinions recommendation of Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718073986.793497271 ◽

2014 ◽

Author(s):

Stephan Stilgenbauer

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Mantle Cell Lymphoma ◽

Peripheral Blood ◽

Kinase Inhibitor ◽

Cell Lymphoma ◽

Mantle Cell ◽

Bruton Tyrosine Kinase

Download Full-text